Remdesivir for Severely Ill Inpatients With COVID-19 (An ACTIV-3b/TESICO Treatment Trial)

Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2024
This study looks at the safety and effectiveness of Remdesivir in treating COVID-19 in people who have been hospitalized with the infection and who have acute respiratory failure. Participants in the study will be treated with Remdesivir plus current standard of care (SOC), or with placebo plus current SOC.
Epistemonikos ID: d259aaf5e86e3f3c71ebaaf5e838da0fb4ae179a
First added on: Dec 12, 2024